Please provide your email address to receive an email when new articles are posted on . LOUISVILLE, Ky. — Persistent, chronic inflammation seen in moderate to severe psoriasis is associated with ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

A close-up of bad psoriasis on a person’s arm Does systemic agent prescribing for psoriasis vary by season or other exacerbating factors? Seasonal variations in psoriasis therapy initiation may help ...

Please provide your email address to receive an email when new articles are posted on . Systemic medications for the treatment of pediatric psoriasis failed to increase serious infection risk, ...

Approximately 14,280 more US patients with psoriasis were estimated to initiate a biologic in Spring than in other seasons, and over 840 more biologic users switched in Spring than in Winter. Season, ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with plaque psoriasis, studies have shown that ...

Patients with psoriasis often have comorbidities that are linked to the systemic inflammation of psoriasis and its treatment, according to study findings published in The Journal of Dermatology. The ...

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis. Half of ...

Older adults with severe or refractory psoriatic disease face a unique challenge: Balancing the need for effective systemic treatment with the increased risk for serious infections. A cohort study ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...